Dell’Oglio P, et al. - Experts herein, studied the overall survival benefit and cost in high metastatic risk prostate cancer (PCa) patients treated with a combination of androgen deprivation therapy (ADT) at radiotherapy (RT) relative to RT alone. As per the results, the combination of ADT at RT did not appear to reduce the cancer-specific mortality (CSM) rates in high metastatic risk PCa patients aged 80 years or more. A substantial increase was noted in cost due to the use of the combination of ADT at RT when compared to RT alone.